HOME > TOP STORIES

TOP STORIES

BUSINESS Sawai and 7 Other Generic Makers Seeking Lyrica Patent Invalidity

February 4, 2019
BUSINESS Oncolys Plans to Begin Japan PII Study of Oncolytic Virus in 2nd Half of 2019

February 1, 2019
REGULATORY Faulty Wage Data Might Have Affected Drug Pricing as Labor Stats Used for Cost-Based Method

January 31, 2019
TRENDS Drug Formulary Initiatives Moving Beyond Hospitals, Generic Makers Prepping for Regional Lists

January 30, 2019
BUSINESS Nippon Express to Set Up 4 Distribution Centers for Full-Scale Drug Logistics Biz, Aims for 15 Billion Yen Annual Sales

January 29, 2019
BUSINESS Xofluza Enjoys Commanding Lead with 47% Share in October-December, MHLW Data Show

January 28, 2019
BUSINESS Takeda’s Specialty Business Unit Boots Up with Entyvio Detailing

January 25, 2019
REGULATORY MHLW Unveils Outline of Cost-Effective Assessment Scheme: Chuikyo

January 24, 2019
BUSINESS Mitsubishi Tanabe Eyes US as 1st Launch Market, Zeroes in on Immunology/CNS: Chief

January 22, 2019
BUSINESS Shionogi Facing Xofluza Supply Crunch as Flu Season Gets into Full Swing

January 21, 2019
BUSINESS Mitsubishi Tanabe Staffers Tapping New Support System to Balance Work and Infertility, Medical Treatment

January 18, 2019
REGULATORY PMDA to Specify Target Overall Review Period for Regenerative Medicine Products: FY2019-2023 Plan

January 17, 2019
REGULATORY MHLW Won’t Necessarily Push March Announcement of New Drug Prices: Bureau Head

January 16, 2019
BUSINESS Japan Pharma Market Sags 2% in April-December as Pricing Overhaul Weighs: Encise

January 15, 2019
REGULATORY PMDA to Raise Fees and Expand Workforce to Boost Review and Safety Measures, GMP Inspection

January 15, 2019
COMMENTARY 2019 Likely to Herald Burst of “Regenerative Medicine” Approvals

January 11, 2019
REGULATORY MHLW to Revise Biosimilar Guidelines to Increase Efficiency in Development, Review; Final Draft Expected in FY2019

January 10, 2019
REGULATORY MHLW Approves Amgen/Astellas’ Evenity, Gilead Sciences’ Epclusa and More

January 9, 2019
BUSINESS Takeda Completes £46 Billion Shire Acquisition

January 8, 2019
REGULATORY MHLW to Follow Up on Drug Makers’ Efforts to Observe New Detailing Guidelines

January 7, 2019

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch

By Ken Yoshino

Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…